11-5226762-CA-CAA
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_000518.5(HBB):c.129dupT(p.Glu44fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. F43F) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000518.5 frameshift
Scores
Clinical Significance
Conservation
Publications
- dominant beta-thalassemiaInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), ClinGen
- hemoglobin M diseaseInheritance: AD Classification: DEFINITIVE, MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, ClinGen
- beta thalassemiaInheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women’s Health
- beta-thalassemia HBB/LCRBInheritance: AR, SD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- sickle cell disease and related diseasesInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- erythrocytosis, familial, 6Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Heinz body anemiaInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- sickle cell diseaseInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)
- hereditary persistence of fetal hemoglobin-beta-thalassemia syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- beta-thalassemia intermediaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- beta-thalassemia majorInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- delta-beta-thalassemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hemoglobin C diseaseInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hemoglobin C-beta-thalassemia syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hemoglobin E diseaseInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hemoglobin E-beta-thalassemia syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary persistence of fetal hemoglobin-sickle cell disease syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- sickle cell-beta-thalassemia disease syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- sickle cell-hemoglobin c disease syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- sickle cell-hemoglobin d disease syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- sickle cell-hemoglobin E disease syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hemoglobinopathy Pathogenic:1
Variant summary: HBB c.129dupT (p.Glu44X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251398 control chromosomes. c.129dupT has been reported in the literature in at least one individual affected with beta-thallasemia (e.g. Oshima_1996). In addition, a different variant, c.130G>T, which results in the same nonsense amino acid change, p.Glu44X, has been reported in multiple individuals with beta-thalassemia or other hemoglobinpathies in the literature (e.g. Tan_2006, Tang_2015, Peng_2020). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One other ClinVar submitter (evaluation after 2014) has cited the variant as Pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
beta Thalassemia Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at